Shareholders in GlaxoSmithKline (GSK) really only have to answer one question: will they benefit when the group is taken over or broken up? There seems little hope that Glaxo can arrest its decline through its own efforts, therefore the responsibility will fall to a third party. Will that be good for shareholders, or should they exit now before the share price, which has been sinking for years, is blown out of the water by the dividend cut that looks just one corporate foul-up away?
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis